FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153485290> ?p ?o ?g. }

• W2153485290 endingPage "250.e1" @default.
• W2153485290 startingPage "243" @default.
• W2153485290 abstract "Background Few studies have investigated the treatment and the outcomes of patients with catheter-related thrombosis (CRT). Methods The RIETE registry (Registro Informatizado de Enfermedad TromboEmbólica [Computerized Registry of Patients with Venous Thromboembolism]) is a prospective international registry of consecutive patients with objectively confirmed venous thromboembolism (VTE). We analyzed the characteristics, treatment, and outcomes of patients with CRT. Results Of 558 patients with CRT, 45 (8%) presented with a pulmonary embolism (PE) concomitantly. More patients had central line-associated thrombosis compared with port systems, but catheter type did not influence the risk of presenting with a PE. Patients with only CRT were more often prescribed low-molecular-weight heparin for the duration of their anticoagulant treatment compared with patients presenting with concomitant PE. VTE recurrences and major bleeding events occurred frequently during treatment with anticoagulation (7 per 100 patient-years and 8.9 per 100 patient years, respectively). The rates of fatal PE recurrences (1.85 per 100 patient-years) and fatal bleeding (2.32 per 100 patient-years) were similar. Patients with an additional transient risk factor for VTE had the lowest risk for VTE recurrences (odds ratio [OR], 0.07; 90% confidence interval [CI], 0.01-0.45) compared with patients with CRT and no additional transient risk factors. PE at presentation increased the risk of recurrent thrombosis by 2.4 times. Renal insufficiency was also an independent predictor of recurrent thrombosis (OR, 3.93; 90% CI, 2.0-7.7). The odds of recurrent thrombosis was decreased by 77% in patients who received anticoagulation therapy for >90 days compared with patients with a shorter treatment (OR, 0.23; 90% CI, 0.1-0.56). Conclusions Concomitant PE occurs less frequently in CRT than lower extremity deep venous thrombosis, but it is associated with a worse outcome. CRT occurs in high-risk patients, and duration of anticoagulation must be predicated on balancing these risks. Few studies have investigated the treatment and the outcomes of patients with catheter-related thrombosis (CRT). The RIETE registry (Registro Informatizado de Enfermedad TromboEmbólica [Computerized Registry of Patients with Venous Thromboembolism]) is a prospective international registry of consecutive patients with objectively confirmed venous thromboembolism (VTE). We analyzed the characteristics, treatment, and outcomes of patients with CRT. Of 558 patients with CRT, 45 (8%) presented with a pulmonary embolism (PE) concomitantly. More patients had central line-associated thrombosis compared with port systems, but catheter type did not influence the risk of presenting with a PE. Patients with only CRT were more often prescribed low-molecular-weight heparin for the duration of their anticoagulant treatment compared with patients presenting with concomitant PE. VTE recurrences and major bleeding events occurred frequently during treatment with anticoagulation (7 per 100 patient-years and 8.9 per 100 patient years, respectively). The rates of fatal PE recurrences (1.85 per 100 patient-years) and fatal bleeding (2.32 per 100 patient-years) were similar. Patients with an additional transient risk factor for VTE had the lowest risk for VTE recurrences (odds ratio [OR], 0.07; 90% confidence interval [CI], 0.01-0.45) compared with patients with CRT and no additional transient risk factors. PE at presentation increased the risk of recurrent thrombosis by 2.4 times. Renal insufficiency was also an independent predictor of recurrent thrombosis (OR, 3.93; 90% CI, 2.0-7.7). The odds of recurrent thrombosis was decreased by 77% in patients who received anticoagulation therapy for >90 days compared with patients with a shorter treatment (OR, 0.23; 90% CI, 0.1-0.56). Concomitant PE occurs less frequently in CRT than lower extremity deep venous thrombosis, but it is associated with a worse outcome. CRT occurs in high-risk patients, and duration of anticoagulation must be predicated on balancing these risks." @default.
• W2153485290 created "2016-06-24" @default.
• W2153485290 creator A5000764814 @default.
• W2153485290 creator A5001665249 @default.
• W2153485290 creator A5002791203 @default.
• W2153485290 creator A5002908768 @default.
• W2153485290 creator A5003245068 @default.
• W2153485290 creator A5004653505 @default.
• W2153485290 creator A5009345884 @default.
• W2153485290 creator A5010238262 @default.
• W2153485290 creator A5010872053 @default.
• W2153485290 creator A5010930677 @default.
• W2153485290 creator A5011394456 @default.
• W2153485290 creator A5011821801 @default.
• W2153485290 creator A5012451306 @default.
• W2153485290 creator A5012505394 @default.
• W2153485290 creator A5013161600 @default.
• W2153485290 creator A5013725675 @default.
• W2153485290 creator A5013886476 @default.
• W2153485290 creator A5014919477 @default.
• W2153485290 creator A5015151469 @default.
• W2153485290 creator A5016522360 @default.
• W2153485290 creator A5016735257 @default.
• W2153485290 creator A5017713447 @default.
• W2153485290 creator A5018185321 @default.
• W2153485290 creator A5018414502 @default.
• W2153485290 creator A5019271110 @default.
• W2153485290 creator A5020660579 @default.
• W2153485290 creator A5020881196 @default.
• W2153485290 creator A5021135979 @default.
• W2153485290 creator A5021412849 @default.
• W2153485290 creator A5021418522 @default.
• W2153485290 creator A5021741191 @default.
• W2153485290 creator A5021815115 @default.
• W2153485290 creator A5021827783 @default.
• W2153485290 creator A5021929797 @default.
• W2153485290 creator A5023115317 @default.
• W2153485290 creator A5023227285 @default.
• W2153485290 creator A5023847182 @default.
• W2153485290 creator A5024960940 @default.
• W2153485290 creator A5025659158 @default.
• W2153485290 creator A5025928709 @default.
• W2153485290 creator A5026105840 @default.
• W2153485290 creator A5026388140 @default.
• W2153485290 creator A5026788917 @default.
• W2153485290 creator A5027251508 @default.
• W2153485290 creator A5027956417 @default.
• W2153485290 creator A5028382767 @default.
• W2153485290 creator A5028817509 @default.
• W2153485290 creator A5030192067 @default.
• W2153485290 creator A5031073279 @default.
• W2153485290 creator A5033014191 @default.
• W2153485290 creator A5034116023 @default.
• W2153485290 creator A5034216222 @default.
• W2153485290 creator A5034535859 @default.
• W2153485290 creator A5035627815 @default.
• W2153485290 creator A5036305590 @default.
• W2153485290 creator A5036972437 @default.
• W2153485290 creator A5037169706 @default.
• W2153485290 creator A5037296283 @default.
• W2153485290 creator A5039153064 @default.
• W2153485290 creator A5040991094 @default.
• W2153485290 creator A5041649569 @default.
• W2153485290 creator A5041913515 @default.
• W2153485290 creator A5044470561 @default.
• W2153485290 creator A5044994056 @default.
• W2153485290 creator A5046546129 @default.
• W2153485290 creator A5047042268 @default.
• W2153485290 creator A5047145682 @default.
• W2153485290 creator A5047467120 @default.
• W2153485290 creator A5047695103 @default.
• W2153485290 creator A5047893736 @default.
• W2153485290 creator A5047949332 @default.
• W2153485290 creator A5048937409 @default.
• W2153485290 creator A5049423941 @default.
• W2153485290 creator A5049545273 @default.
• W2153485290 creator A5049938054 @default.
• W2153485290 creator A5050659688 @default.
• W2153485290 creator A5050923155 @default.
• W2153485290 creator A5051226414 @default.
• W2153485290 creator A5051939283 @default.
• W2153485290 creator A5052390979 @default.
• W2153485290 creator A5053117986 @default.
• W2153485290 creator A5053666939 @default.
• W2153485290 creator A5053827198 @default.
• W2153485290 creator A5053994409 @default.
• W2153485290 creator A5054312456 @default.
• W2153485290 creator A5055060952 @default.
• W2153485290 creator A5055169096 @default.
• W2153485290 creator A5055724080 @default.
• W2153485290 creator A5055826774 @default.
• W2153485290 creator A5057146345 @default.
• W2153485290 creator A5057802451 @default.
• W2153485290 creator A5058647804 @default.
• W2153485290 creator A5058810725 @default.
• W2153485290 creator A5060697224 @default.
• W2153485290 creator A5060707330 @default.
• W2153485290 creator A5061308339 @default.

• next